Although
mitochondria have been identified as a potential therapeutic
target for the treatment of various diseases, inefficient drug targeting
to mitochondria is a major limitation for related therapeutic applications.
In the current approach, drug loaded nanoscale carriers are used for
mitochondria targeting via endocytic uptake. However, these approaches
show poor therapeutic performance due to inefficient drug delivery
to mitochondria. Here, we report a designed nanoprobe that can enter
the cell via a nonendocytic approach and label mitochondria within
1 h. The designed nanoprobe is <10 nm in size and terminated with
arginine/guanidinium that offers direct membrane penetration followed
by mitochondria targeting. We found five specific criteria that need
to be adjusted in a nanoscale material for mitochondria targeting
via the nonendocytic approach. They include <10 nm size, functionalization
with arginine/guanidinium, cationic surface charge, colloidal stability,
and low cytotoxicity. The proposed design can be adapted for mitochondria
delivery of drugs for efficient therapeutic performance.